Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) had its target price increased by Piper Sandler from $33.00 to $38.00 in a research report report published on Wednesday morning, The Fly reports. The brokerage currently has an overweight rating on the specialty pharmaceutical company's stock.
Supernus Pharmaceuticals Stock Down 1.9 %
Shares of SUPN stock opened at $34.39 on Wednesday. The firm has a fifty day moving average of $31.48 and a 200-day moving average of $30.26. Supernus Pharmaceuticals has a 12-month low of $24.95 and a 12-month high of $36.08. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 34.05 and a beta of 1.04.
Get
Supernus Pharmaceuticals alerts:
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.15). Supernus Pharmaceuticals had a return on equity of 6.98% and a net margin of 9.12%. The company had revenue of $170.10 million for the quarter, compared to the consensus estimate of $164.23 million. During the same period in the prior year, the company earned $0.43 EPS. The firm's revenue was up 20.4% on a year-over-year basis. On average, equities analysts expect that Supernus Pharmaceuticals will post 1.51 EPS for the current year.
Insider Transactions at Supernus Pharmaceuticals
In related news, VP Tami Tillotson Martin sold 5,000 shares of the firm's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $32.98, for a total value of $164,900.00. Following the completion of the transaction, the vice president now owns 87,220 shares of the company's stock, valued at $2,876,515.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, VP Tami Tillotson Martin sold 5,000 shares of the firm's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $32.98, for a total value of $164,900.00. Following the completion of the transaction, the vice president now owns 87,220 shares of the company's stock, valued at $2,876,515.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jack A. Khattar sold 17,302 shares of the firm's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $34.03, for a total transaction of $588,787.06. Following the completion of the transaction, the chief executive officer now directly owns 759,901 shares of the company's stock, valued at approximately $25,859,431.03. The disclosure for this sale can be found here. Insiders sold 66,733 shares of company stock valued at $2,161,863 over the last quarter. Corporate insiders own 7.99% of the company's stock.
Institutional Trading of Supernus Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in the company. Campbell Newman Asset Management Inc. lifted its stake in Supernus Pharmaceuticals by 2.0% in the first quarter. Campbell Newman Asset Management Inc. now owns 22,696 shares of the specialty pharmaceutical company's stock valued at $734,000 after acquiring an additional 443 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Supernus Pharmaceuticals by 2.3% in the second quarter. Exchange Traded Concepts LLC now owns 19,472 shares of the specialty pharmaceutical company's stock valued at $563,000 after acquiring an additional 444 shares during the last quarter. Maryland State Retirement & Pension System lifted its stake in Supernus Pharmaceuticals by 2.2% in the first quarter. Maryland State Retirement & Pension System now owns 21,511 shares of the specialty pharmaceutical company's stock valued at $695,000 after acquiring an additional 460 shares during the last quarter. Retirement Planning Co of New England Inc. lifted its stake in Supernus Pharmaceuticals by 1.3% in the first quarter. Retirement Planning Co of New England Inc. now owns 37,969 shares of the specialty pharmaceutical company's stock valued at $1,227,000 after acquiring an additional 488 shares during the last quarter. Finally, Pitcairn Co. lifted its stake in Supernus Pharmaceuticals by 6.2% in the first quarter. Pitcairn Co. now owns 8,999 shares of the specialty pharmaceutical company's stock valued at $291,000 after acquiring an additional 523 shares during the last quarter. Institutional investors and hedge funds own 99.81% of the company's stock.
About Supernus Pharmaceuticals
(Get Rating)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
Featured Stories
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
